|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Bristol-Myers Squibb |
| Information provided by: | Bristol-Myers Squibb |
| ClinicalTrials.gov Identifier: | NCT00035529 |
Purpose
The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo
| Condition | Intervention | Phase |
|
Multiple Sclerosis |
Drug: CTLA4Ig |
Phase II |
| MedlinePlus related topics: | Multiple Sclerosis |
| ChemIDplus related topics: | Abatacept Cytotoxic T-lymphocyte antigen 4 |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | A Phase II,Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-Remitting Multiple Sclerosis |
Eligibility
| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion
Exclusion
Contacts and Locations| United States, Connecticut | |||||
| Local Institution | |||||
| New Haven, Connecticut, United States | |||||
| United States, Kentucky | |||||
| Local Institution | |||||
| Louisville, Kentucky, United States | |||||
| United States, Massachusetts | |||||
| Local Institution | |||||
| Worcester, Massachusetts, United States | |||||
| United States, New Jersey | |||||
| Local Institution | |||||
| Newark, New Jersey, United States | |||||
| United States, New York | |||||
| Local Institution | |||||
| New York, New York, United States | |||||
| United States, North Carolina | |||||
| Local Institution | |||||
| Charlotte, North Carolina, United States | |||||
| United States, Pennsylvania | |||||
| Local Institution | |||||
| Philadelphia, Pennsylvania, United States | |||||
| United States, Texas | |||||
| Local Institution | |||||
| Dallas, Texas, United States | |||||
| United States, Vermont | |||||
| Local Institution | |||||
| Burlington, Vermont, United States | |||||
| United States, Wisconsin | |||||
| Local Institution | |||||
| Madison, Wisconsin, United States | |||||
| Bristol-Myers Squibb |
More Information
BMS Clinical Trials Disclosure 
  |
For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm 
  |
| Study ID Numbers: | IM101-200 |
| First Received: | May 3, 2002 |
| Last Updated: | September 26, 2007 |
| ClinicalTrials.gov Identifier: | NCT00035529 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|